Short Courses

Gene Editing for Drug Discovery

Sunday, February 4
8:00 AM - 11:15 AM
Location: 16B

Genome editing tools such as CRISPR-Cas9 are reshaping what is possible within the biological sciences. This course will introduce the possibilities of what can be achieved with genome editing, the current limitations, and the fundamentals of how to apply these technologies to enhance the pursuit of targets and therapeutics.

Additional fees apply. Visit http://www.slas2018.org/program/short-course-program/ for more information.

John G. Doench

Associate Director, Genetic Perturbation Platform
Broad Institute of MIT and Harvard

John G. Doench is the Associate Director of the Genetic Perturbation Platform at the Broad Institute. He develops and applies the latest approaches in functional genomics, including RNAi, ORF, and CRISPR technologies, to understand the function of genes and how gene dysfunction leads to disease. John collaborates with researchers across the Broad, the Boston community, and the world to develop faithful biological models and execute genetic screens.

Prior to joining the Broad in 2009, John did his postdoctoral work at Harvard Medical School, received his PhD from the biology department at MIT, and majored in history at Hamilton College. John lives in Jamaica Plain, MA with his wife and daughter, where he enjoys coaching soccer, playing volleyball, cheering on the Red Sox and Patriots, and avoiding imminent death while navigating the streets of Boston on a bicycle.

Presentation(s):

Send Email for John Doench

Samuel A. Hasson

Principal Investigator, Lab Head
Pfizer, Inc.

Presentation(s):

Send Email for Samuel Hasson


Assets

Gene Editing for Drug Discovery



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Gene Editing for Drug Discovery